-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationMaterial
On March 29, Pfizer and BioNTech announced that the U.
In addition, the FDA has authorized the vaccine for a second booster dose for individuals 12 years of age and older, identified as having certain immunocompromised conditions, who have received any of the approved COVID-19 boosters
The expanded EUA is based on clinical trial data provided by the two companies, one of which was an open-label pilot study conducted at a medical center in Israel involving 154 people 18 years of age and older
Previously, the Pfizer-BioNTech COVID-19 vaccine has been authorized by the EUA as a single booster dose for people 12 years of age and older who have completed primary vaccination against the disease
It is understood that vaccination in the United States is divided into primary and booster series of vaccinations
Reference source: Pfizer and BioNTech Receive Expanded US Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
